Healthcare Sector ETFs: Steady Growth Opportunity
Health care is the rare sector that is both defensive and growing, backed by aging populations. But policy risk and concentration in a few giants make XLV and VHT more nuanced than they look.
Don't have time? Here's what you need to know:
- 1Health care is the rare sector that is both defensive and growing, backed by an aging-population tailwind.
- 2XLV (~0.09%) covers S&P 500 health care; VHT (~0.10%) adds hundreds of mid- and small-cap names.
- 3The dominant risk is regulatory, drug pricing and reform headlines, not the ordinary business cycle.
- 4Both funds lean heavily on a few large pharma and insurer names, so they're more concentrated than the holding count implies.
Why Health Care Is an Unusual Sector
Most sectors force a trade-off: defensive sectors are stable but slow, while growth sectors are exciting but volatile. Health care is the rare one that offers a bit of both. People need medicine, hospitals, and insurance in good times and bad, which gives the sector defensive resilience in downturns. Yet aging populations and a steady pipeline of new drugs and devices give it a long-term growth tailwind that pure defensives like utilities lack.
The two broad funds most investors use are the Health Care Select Sector SPDR (XLV) at about 0.09% and Vanguard's VHT at roughly 0.10%. Both hold a mix of pharmaceutical giants, biotech firms, medical-device makers, and health insurers. The difference is breadth: VHT holds several hundred names including more small- and mid-caps, while XLV concentrates on the large-cap leaders of the S&P 500's health-care slice.
The Demographic Tailwind Behind the Sector
The structural case for health care is demographics. The share of the population over 65 is rising across the developed world, and older people consume far more health care than younger ones. That trend is slow, durable, and largely independent of the business cycle, which is exactly the kind of tailwind long-term investors prize. It does not guarantee returns, but it underpins steady demand for the sector's products for decades to come.
Layered on top is innovation. Advances in biologics, gene therapy, weight-loss drugs, and medical devices periodically create entirely new multibillion-dollar markets. The flip side is that drug development is expensive and uncertain, with most candidates failing in trials, so the sector blends defensive demand with pockets of genuine growth-stock risk, especially in biotech.
Tip: Health care's appeal is the combination of defensive demand and a demographic growth tailwind. That dual nature is why it often behaves differently from both pure defensives and pure growth sectors.
The Policy Risk Nobody Fully Prices
The biggest wild card for health care is not the economy, it is politics. Drug pricing, insurance regulation, and reform proposals can move the sector sharply, and headlines around elections or major legislation regularly spike volatility. A single policy announcement on drug-price negotiation can hit pharmaceutical valuations in a way that has nothing to do with a company's underlying business.
This is the trade-off for the sector's stability. Health care is insulated from the ordinary business cycle but exposed to a political cycle that is harder to predict. For long-term holders, the durable demographic demand has historically outweighed periodic policy scares, but anyone overweighting the sector should expect occasional sharp, headline-driven drawdowns that have little to do with fundamentals.
Important: Health care's main risk is regulatory, not economic. Drug-pricing and reform headlines can move the sector hard and fast, independent of company earnings.
Ready to invest? Open an IBKR account in 10 minutes and get free stock. $0 commissions on US ETFs • Fractional shares from $1 • 150+ global markets.
Concentration and How the Funds Are Built
Like most cap-weighted sector funds, XLV is concentrated at the top. A handful of giant pharmaceutical and managed-care companies typically make up a large share of the fund, so its performance leans heavily on a few names. VHT spreads exposure across more holdings, which dilutes single-stock risk somewhat but still tilts toward the same large-cap leaders. Neither is as diversified as the headline holding count suggests.
| XLV | VHT | |
|---|---|---|
| Issuer | State Street | Vanguard |
| Expense ratio | ~0.09% | ~0.10% |
| Coverage | S&P 500 health care | Broad U.S. health care |
| Holdings | ~60 | ~400+ |
| Cap focus | Large-cap | Large with mid/small tilt |
| Sub-industries | Pharma, devices, insurers, biotech | Same, broader |
Fitting Health Care Into a Portfolio
Health care already makes up a meaningful chunk of any broad index fund, so the first question is whether you want more than the market already gives you. Investors who want a defensive tilt with a growth angle sometimes add a modest XLV or VHT position, sized as a satellite rather than a core holding. Compared with pairing tech against the index, a health-care tilt overlaps less with mega-cap concentration, which some investors view as a diversification benefit.
If you are choosing between a defensive sector for stability, our XLP vs XLV comparison contrasts health care with consumer staples, and our XLK vs XLV comparison shows how it stacks up against a pure growth sector. Browse vetted funds on the health care sector ETFs page.
Want the full framework? This 2-hour ETF course teaches you exactly how to pick, buy, and hold profitable ETFs — from zero to confident investor. Under $15.
Frequently Asked Questions
Is health care a defensive or a growth sector?
It's genuinely both, which is what makes it unusual. The defensive side comes from steady demand for medicine, hospitals, and insurance regardless of the economy. The growth side comes from aging populations and continuous innovation in drugs and devices. This dual nature means health care often holds up better than growth sectors in downturns while still offering more upside than pure defensives like utilities.
What is the biggest risk in healthcare ETFs?
Policy and regulation, not the business cycle. Drug-pricing legislation, insurance reform, and election-driven uncertainty can move the sector sharply and quickly, independent of how individual companies are performing. Biotech holdings add a second risk, since most drug candidates fail in clinical trials. For long-term holders, durable demographic demand has historically outweighed these scares, but expect occasional headline-driven volatility.
What's the difference between XLV and VHT?
XLV tracks the health-care slice of the S&P 500, so it holds about 60 large-cap names at roughly 0.09%. VHT is Vanguard's broader version with 400-plus holdings, including more mid- and small-cap companies, at about 0.10%. Both lean heavily on the same large pharmaceutical and managed-care giants, so their returns are usually similar, with VHT giving slightly wider exposure.
Further Reading
Free Tools
Alex Harrington
CFA Level II Candidate, Finance & Economics
Alex Harrington is an independent ETF researcher and personal finance writer with over 8 years of experience analyzing exchange-traded funds. A CFA Level II candidate with a background in economics, Alex has reviewed 800+ ETFs and helped thousands of beginners build their first investment portfolios through clear, jargon-free education.
This content is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.